The data presented at the conference included post-hoc, positive data indicating a potential benefit of treatment with azeliragon in AD patients with type 2 diabetes. It is estimated that nearly 40 percent of Medicare beneficiaries age 65 and older with dementia also have diabetes...
No comment necessary.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”